1.
Ugeskr Laeger
; 180(45)2018 Nov 05.
Artigo
em Dinamarquês
| MEDLINE
| ID: mdl-30404716
RESUMO
Recent reports imply, that denosumab discontinuation may lead to an increased risk of multiple vertebral fractures. This is a case report about two postmenopausal women, both with previous fragility fractures, who presented multiple vertebral fractures after denosumab discontinuation. One of the women also had symptomatic hypoparathyroid hypercalcaemia, six months after denosumab was discontinued. We recommend, that denosumab treatment should not be stopped without considering an alternative treatment.